Company news

Iovance Biotherapeutics, Inc. news in 2023

Iovance Biotherapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer

December 26, 2023

Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates

November 6, 2023

Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023

October 30, 2023

Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Advanced Mucosal Melanoma at the European Society for Medical Oncology (ESMO) Congress

October 15, 2023

Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates

August 7, 2023

Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering

July 12, 2023

Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock

July 9, 2023

Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock

July 9, 2023

Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer

July 9, 2023

Iovance Biotherapeutics Announces First Patient Randomized in Phase 3 TILVANCE-301 Trial in Frontline Advanced Melanoma

June 14, 2023

Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma

May 25, 2023

Iovance Biotherapeutics Reports First Quarter 2023 Financial Results and Corporate Updates

May 8, 2023

Iovance Biotherapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, May 9, 2023

May 1, 2023

Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma

March 23, 2023

Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates

February 27, 2023

Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, February 28, 2023

February 20, 2023

Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates

January 22, 2023

Calls in 2023

Decks in 2023